Unlike its mutations difficult to target in cancers, p53 is often wild-type in mature neurons which are impaired by stroke and neurodegenerative diseases, and the discovery of therapeutic drugs targeting Mdm2/Mdmx–p53 interactions in clinics can be potentially useful in AML, multiple myeloma, and other hematological malignancies54. This evidence concerns the gene TP53 and AL amyloidosis.